CN119431581A - 抗原结合蛋白 - Google Patents
抗原结合蛋白 Download PDFInfo
- Publication number
- CN119431581A CN119431581A CN202411387665.2A CN202411387665A CN119431581A CN 119431581 A CN119431581 A CN 119431581A CN 202411387665 A CN202411387665 A CN 202411387665A CN 119431581 A CN119431581 A CN 119431581A
- Authority
- CN
- China
- Prior art keywords
- seq
- acid sequence
- binding protein
- amino acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906876P | 2019-09-27 | 2019-09-27 | |
| US62/906,876 | 2019-09-27 | ||
| US202063057508P | 2020-07-28 | 2020-07-28 | |
| US63/057,508 | 2020-07-28 | ||
| CN202080080763.5A CN114729049B (zh) | 2019-09-27 | 2020-09-25 | 抗原结合蛋白 |
| PCT/EP2020/076834 WO2021058711A2 (en) | 2019-09-27 | 2020-09-25 | Antigen binding proteins |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080080763.5A Division CN114729049B (zh) | 2019-09-27 | 2020-09-25 | 抗原结合蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119431581A true CN119431581A (zh) | 2025-02-14 |
Family
ID=72840475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411387665.2A Pending CN119431581A (zh) | 2019-09-27 | 2020-09-25 | 抗原结合蛋白 |
| CN202080080763.5A Active CN114729049B (zh) | 2019-09-27 | 2020-09-25 | 抗原结合蛋白 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080080763.5A Active CN114729049B (zh) | 2019-09-27 | 2020-09-25 | 抗原结合蛋白 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11479607B2 (enExample) |
| EP (1) | EP4034562B1 (enExample) |
| JP (3) | JP7280387B2 (enExample) |
| KR (1) | KR20220070011A (enExample) |
| CN (2) | CN119431581A (enExample) |
| AU (1) | AU2020355614B2 (enExample) |
| BR (1) | BR112022005787A2 (enExample) |
| CA (1) | CA3155173A1 (enExample) |
| CO (1) | CO2022003053A2 (enExample) |
| IL (1) | IL291364A (enExample) |
| MX (1) | MX2022003523A (enExample) |
| MY (1) | MY207830A (enExample) |
| PH (1) | PH12022550671A1 (enExample) |
| TW (1) | TWI865617B (enExample) |
| WO (1) | WO2021058711A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020355614B2 (en) * | 2019-09-27 | 2024-12-05 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| CR20250009A (es) | 2022-06-17 | 2025-05-07 | Apogee Biologics Inc | Anticuerpos que se unen a interleuquina 13 y métodos de uso |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| KR100829674B1 (ko) | 2000-05-19 | 2008-05-16 | 코릭사 코포레이션 | 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 |
| AU8100101A (en) | 2000-08-04 | 2002-02-18 | Corixa Corp | New immunoeffector compounds |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2097535B1 (en) | 2006-12-07 | 2016-09-21 | The Board of Trustees of the Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| EP2068925A4 (en) | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| SG186656A1 (en) | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP3605088A1 (en) | 2008-04-09 | 2020-02-05 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| EA031849B1 (ru) | 2010-08-23 | 2019-03-29 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ox40 и способы их применения |
| AU2012233652B2 (en) | 2011-03-31 | 2017-05-18 | Centre Leon Berard | Antibodies directed against ICOS and uses thereof |
| BR122022000334B1 (pt) | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| AR093788A1 (es) | 2012-12-04 | 2015-06-24 | Oncomed Pharm Inc | Inmunoterapia con agentes de enlace |
| RU2702108C2 (ru) | 2013-07-16 | 2019-10-04 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit |
| JP2016530267A (ja) * | 2013-08-22 | 2016-09-29 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| HUE063307T2 (hu) * | 2013-08-22 | 2024-01-28 | The Council Of The Queensland | Rák és vírusfertõzések kezelésére szolgáló immunreceptor-moduláció |
| US20160355589A1 (en) * | 2014-08-19 | 2016-12-08 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| EP3565889B1 (en) * | 2017-01-06 | 2025-03-26 | ImmunityBio, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| JP2020530859A (ja) * | 2017-08-11 | 2020-10-29 | ブリンク バイオメディカル エスエーエス | 免疫調節剤としてのｃｄ９６結合剤 |
| WO2019091449A1 (zh) | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| WO2021042019A1 (en) | 2019-08-30 | 2021-03-04 | Agenus Inc. | Anti-cd96 antibodies and methods of use thereof |
| AU2020355614B2 (en) * | 2019-09-27 | 2024-12-05 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
-
2020
- 2020-09-25 AU AU2020355614A patent/AU2020355614B2/en active Active
- 2020-09-25 WO PCT/EP2020/076834 patent/WO2021058711A2/en not_active Ceased
- 2020-09-25 BR BR112022005787A patent/BR112022005787A2/pt unknown
- 2020-09-25 PH PH1/2022/550671A patent/PH12022550671A1/en unknown
- 2020-09-25 MY MYPI2022001598A patent/MY207830A/en unknown
- 2020-09-25 KR KR1020227014021A patent/KR20220070011A/ko active Pending
- 2020-09-25 JP JP2021571490A patent/JP7280387B2/ja active Active
- 2020-09-25 CA CA3155173A patent/CA3155173A1/en active Pending
- 2020-09-25 MX MX2022003523A patent/MX2022003523A/es unknown
- 2020-09-25 EP EP20789858.6A patent/EP4034562B1/en active Active
- 2020-09-25 TW TW109133431A patent/TWI865617B/zh active
- 2020-09-25 CN CN202411387665.2A patent/CN119431581A/zh active Pending
- 2020-09-25 CN CN202080080763.5A patent/CN114729049B/zh active Active
-
2021
- 2021-11-19 US US17/530,849 patent/US11479607B2/en active Active
-
2022
- 2022-03-14 IL IL291364A patent/IL291364A/en unknown
- 2022-03-16 CO CONC2022/0003053A patent/CO2022003053A2/es unknown
- 2022-09-02 US US17/902,305 patent/US20230279106A1/en active Pending
-
2023
- 2023-05-10 JP JP2023078141A patent/JP7546723B2/ja active Active
-
2024
- 2024-08-20 JP JP2024139180A patent/JP2024167261A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4034562C0 (en) | 2025-10-29 |
| BR112022005787A2 (pt) | 2022-06-21 |
| AU2020355614B2 (en) | 2024-12-05 |
| MX2022003523A (es) | 2022-04-25 |
| JP2024167261A (ja) | 2024-12-03 |
| US11479607B2 (en) | 2022-10-25 |
| WO2021058711A3 (en) | 2021-06-03 |
| JP2022535034A (ja) | 2022-08-04 |
| MY207830A (en) | 2025-03-21 |
| EP4034562A2 (en) | 2022-08-03 |
| PH12022550671A1 (en) | 2023-05-29 |
| CA3155173A1 (en) | 2021-04-01 |
| US20230279106A1 (en) | 2023-09-07 |
| TW202128755A (zh) | 2021-08-01 |
| WO2021058711A2 (en) | 2021-04-01 |
| IL291364A (en) | 2022-05-01 |
| KR20220070011A (ko) | 2022-05-27 |
| US20220089728A1 (en) | 2022-03-24 |
| JP2023103352A (ja) | 2023-07-26 |
| EP4034562B1 (en) | 2025-10-29 |
| CN114729049B (zh) | 2024-10-25 |
| TWI865617B (zh) | 2024-12-11 |
| JP7546723B2 (ja) | 2024-09-06 |
| CO2022003053A2 (es) | 2022-04-19 |
| CN114729049A (zh) | 2022-07-08 |
| JP7280387B2 (ja) | 2023-05-23 |
| AU2020355614A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7305822B2 (ja) | 組合せ処置およびその方法 | |
| CN110382545A (zh) | 用抗pd-1抗体治疗癌症的方法 | |
| JP2021521182A (ja) | Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療 | |
| KR20180088907A (ko) | Pd-1에 대한 항체 분자 및 그의 용도 | |
| CN114272371A (zh) | 包含抗pd-1抗体分子的联合疗法 | |
| JP2024167261A (ja) | 抗原結合タンパク質 | |
| CN114980902A (zh) | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 | |
| US20220098303A1 (en) | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof | |
| CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| US20240166747A1 (en) | Antigen binding proteins and combinations thereof | |
| RU2827188C1 (ru) | Антигенсвязывающие белки | |
| WO2021227156A1 (en) | Compositions and methods for treating cancer | |
| RU2788092C2 (ru) | Молекулы антител к pd-1 и их применения | |
| CN115038466A (zh) | 联合治疗及其用途和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: United Kingdom Address after: Steve Niki Applicant after: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd. Address before: British Meader Sykes Applicant before: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd. Country or region before: United Kingdom |
|
| CB02 | Change of applicant information |